CION Ameerpet
Follicular lymphoma is an indolent, slow growing non-Hodgkin lymphoma of the B-cells. It often behaves like a long-term, manageable condition. This guide explains what it is, how it is graded and diagnosed, and how CION's haematology team plans care.
Follicular lymphoma is the most common indolent (slow growing) type of non-Hodgkin lymphoma. It develops from B-lymphocytes — a kind of white blood cell — in the germinal centres of the lymph nodes. Under the microscope, the cells cluster into rounded, "follicle-like" patterns, which is where the name comes from. It is one of the B-cell subtypes explained on our lymphoma hub.
The most important thing to understand is that follicular lymphoma is usually slow growing. Many people have no symptoms at all when it is found, and it can stay stable for months or years. Because it is a slow growing lymphoma, the goal is often long-term control rather than an urgent race to treat — a very different mindset from an aggressive lymphoma such as DLBCL.
This guide walks through the symptoms, how the disease is graded and diagnosed, the treatment choices, and the outlook. For the full picture of lymphoma care and specific drug regimens, see our Lymphoma Treatment in Hyderabad page and our team of lymphoma doctors in Hyderabad.
Follicular lymphoma is the most common indolent (slow-growing) non-Hodgkin lymphoma and the second most common non-Hodgkin lymphoma overall, after diffuse large B-cell lymphoma. Because it is indolent, some people with small, symptom-free disease are safely monitored rather than treated straight away — an approach called watch-and-wait. (Source: NCCN and ESMO clinical practice guidelines for follicular lymphoma.)
Lymphomas are broadly split into slow-growing (indolent) and fast-growing (aggressive) types. Follicular lymphoma sits firmly in the indolent group — and that shapes the whole approach.
Grows over months to years and may cause few or no symptoms. Highly treatable and often behaves like a long-term, manageable condition — but harder to eliminate completely, so it can return over time. Most follicular lymphomas are indolent.
Grows quickly over weeks and usually needs prompt treatment, but is often more curable with intensive therapy. DLBCL is the classic example. Grade 3B follicular lymphoma is treated in this aggressive category.
A minority of follicular lymphomas transform over time into a faster-growing lymphoma, which changes the plan. Recognising this early matters — see follicular lymphoma transformation.
Because it is a slow growing lymphoma, follicular lymphoma often causes few symptoms early on. When signs do appear, the most common are:
These symptoms overlap with many ordinary, harmless conditions — most swollen nodes are not lymphoma. But a lymph node that stays enlarged for more than a few weeks, or any B symptoms, should be checked. Speak to a CION haematologist if you have these signs or a confirmed follicular lymphoma diagnosis.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a follicular lymphoma diagnosis, wondering whether to treat or monitor, or need a second opinion before deciding? CION's haematology and oncology team is here.
Follicular lymphoma is graded 1 to 3 by counting the large cells (centroblasts) a pathologist sees under the microscope. The grade is one of the most important pieces of information because it separates typically indolent disease from a form that behaves aggressively.
| Grade | Cell picture | Typical behaviour |
|---|---|---|
| Grade 1 | Few large cells | Indolent — slow growing |
| Grade 2 | More large cells | Indolent — slow growing |
| Grade 3A | Many large cells, some small cells remain | Usually managed as indolent disease |
| Grade 3B | Sheets of large cells | Treated as an aggressive lymphoma |
Grading and behaviour vary by individual; this table is a general guide. The grade is decided by a pathologist on biopsy tissue. Grading follows current NCCN and ESMO guidance.
Confirming follicular lymphoma — and mapping how far it has spread — takes a step-by-step pathway. CION delivers the biopsy coordination, imaging, bone-marrow exam and pathology review directly.
Diagnosis needs a tissue sample — ideally the removal of a whole affected lymph node (an excisional biopsy), because the pathologist needs to see the follicular growth pattern, not just individual cells. Immunohistochemistry looks for B-cell markers such as CD20 and BCL2, which help confirm the diagnosis and its origin. The tissue is then graded 1 to 3.
A whole-body PET-CT scan shows which lymph node groups are involved and whether the disease has spread beyond the lymph nodes. This defines the stage, which — together with the grade — guides whether treatment is needed now or later.
Because indolent lymphomas often involve the bone marrow, a bone-marrow examination is frequently done to complete staging. Blood tests, including LDH, help build a prognostic picture using tools such as the FLIPI index. NCCN and ESMO guidelines expect this full work-up before a treatment decision is made.
For follicular lymphoma, an excisional (whole-node) biopsy is preferred over a small needle sample. That is because the diagnosis depends on seeing the architecture — the follicle-like pattern — of the tissue, and on grading how many large cells are present. A needle core can miss this and can even miss an area that has already transformed into aggressive disease. (Source: NCCN and ESMO clinical practice guidelines for follicular lymphoma.)
The plan depends on the grade, stage, symptoms and your overall health. Every case is reviewed by CION's multidisciplinary tumour board before the approach is set. Because this is an indolent disease, the first decision is often whether to treat now at all. Specific drug regimens are detailed on the Lymphoma Treatment in Hyderabad page.
For small, symptom-free disease, immediate treatment may add side effects without adding benefit. Instead, the disease is carefully monitored with regular reviews, scans and blood tests, with a clear plan to step in if it grows or causes symptoms. This is a recognised, guideline-backed strategy for indolent lymphoma — not a case of "doing nothing".
When treatment is needed, the usual backbone is an anti-CD20 monoclonal antibody combined with chemotherapy. The antibody targets the CD20 marker on the B-cells, while chemotherapy adds broader cell-killing action. CION's medical oncology team delivers antibody and chemotherapy directly.
After a good response, ongoing maintenance therapy with the antibody can help keep the disease in remission for longer. Whether maintenance is right for you is a discussion balancing longer control against added treatment time.
Truly early-stage disease confined to one area can sometimes be treated with radiation therapy (IMRT) alone, delivered directly at CION, with the aim of long-term control of that site.
For disease that keeps returning or transforms, more intensive options such as stem-cell transplant or CAR-T cell therapy may be considered. CION coordinates these through accredited partner facilities — they are not delivered in-house — while managing your overall pathway and follow-up.
In advanced stages, follicular lymphoma is generally regarded as very treatable rather than curable — but it often behaves like a long-term, manageable condition. Many people live well for many years, with periods of treatment followed by long stretches of good health. Doctors use prognostic tools such as the FLIPI index to estimate risk from factors like age, stage, LDH and the number of node sites involved.
Published series report favourable long-term survival for indolent lymphomas overall. For context on other lymphoma types, aggressive DLBCL has a reported survival of roughly 60–70% in published series, while Hodgkin lymphoma sits around 80–90% — figures always attributed to published data and NCCN/ESMO sources. These are population figures and outcomes vary by individual: grade, stage, age and how the disease responds all matter.
A smaller number of follicular lymphomas transform over time into an aggressive lymphoma, which changes the approach — see follicular lymphoma transformation. For day-to-day realities, our guide to living with an indolent lymphoma may help.
Follicular lymphoma sits within a wider family of B-cell non-Hodgkin lymphomas. If you are researching the exact subtype, these related pages may help:
For the complete map of lymphoma topics, start at the lymphoma hub or find the right specialist at our best lymphoma hospital in Hyderabad page.
Follicular lymphoma carries real nuance, and a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma team — especially valuable when the grade is borderline or you have been advised to start treatment for slow-growing disease.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Follicular lymphoma is the most common type of indolent (slow growing) non-Hodgkin lymphoma. It develops from B-lymphocytes in the germinal centres of lymph nodes, and under the microscope the cells cluster into rounded "follicle-like" patterns — which is how it gets its name. Because follicular lymphoma is usually slow growing, many people have it for months or years before it is diagnosed, often noticed first as a painless swollen lymph node. It is one of the B-cell subtypes covered on our lymphoma hub. Most cases are graded 1 to 3 based on how the cells look. Grades 1, 2 and 3A behave in a typically indolent way, while grade 3B is treated more like an aggressive lymphoma.
For most people, follicular lymphoma is indolent — meaning it is slow growing and can stay stable for long periods, sometimes years, without needing immediate treatment. This is very different from an aggressive lymphoma such as diffuse large B-cell lymphoma (DLBCL), which grows quickly and needs prompt treatment. The trade-off is that indolent lymphomas are harder to eliminate completely and tend to come and go over a lifetime. A small proportion can change character over time into a faster-growing disease — read more on follicular lymphoma transformation to aggressive disease. Grade 3B follicular lymphoma is the exception and is managed as an aggressive lymphoma from the outset.
The most common sign is one or more painless, slowly enlarging lymph nodes — usually in the neck, armpit or groin — that may seem to shrink and swell over weeks. Because this slow growing lymphoma is indolent, many people feel completely well at diagnosis. Some notice so-called "B symptoms": unexplained fever, drenching night sweats, or losing weight without trying. Fatigue, or a feeling of fullness if enlarged nodes press inside the abdomen, can also occur. These symptoms overlap with many harmless conditions, so they are not proof of lymphoma — but a lymph node that stays enlarged for more than a few weeks should be checked. You can discuss any concerning symptom with our team via the consultation form.
Diagnosis needs a biopsy — ideally removal of a whole affected lymph node — so a pathologist can see the follicular growth pattern and confirm the B-cell origin. Immunohistochemistry looks for markers such as CD20 and BCL2, and the tissue is graded 1 to 3 by counting large cells (centroblasts). A PET-CT scan and often a bone-marrow examination map how far the disease has spread (its stage). Blood tests complete the picture. CION delivers the biopsy coordination, imaging, bone-marrow exam and pathology review directly. Accurate grading matters because it separates typical indolent disease (grades 1, 2 and 3A) from grade 3B, which is treated aggressively. See our lymphoma treatment page for what happens after diagnosis.
Because it is slow growing, not every follicular lymphoma needs treatment straight away. When the disease is small and causing no problems, doctors may recommend active monitoring (watch-and-wait). When treatment is needed, the mainstays are an anti-CD20 monoclonal antibody combined with chemotherapy, sometimes followed by maintenance therapy to keep the disease in check for longer. Radiation therapy (IMRT) alone can treat truly localised early-stage disease. NCCN and ESMO guidelines drive these choices. CION delivers chemotherapy, antibody therapy, radiation, bone-marrow assessment and survivorship care directly, and coordinates transplant or CAR-T referral through accredited partner centres when needed. Specific drug regimens are covered on the Lymphoma Treatment in Hyderabad page.
Follicular lymphoma is generally not considered curable in advanced stages, but it is very treatable and often behaves like a long-term, manageable condition — many people live well with it for many years, with periods of treatment followed by long periods of good health. Published series report favourable long-term survival for indolent lymphomas overall, and doctors use tools such as the FLIPI prognostic index to estimate risk. These are population figures and outcomes vary by individual — grade, stage, age and response to treatment all matter. A smaller number of cases transform into an aggressive lymphoma over time, which changes the approach. For a fuller view of living with this diagnosis, see living with an indolent (slow-growing) lymphoma.
Yes. In a minority of people, follicular lymphoma can transform over time into a more aggressive lymphoma — most often diffuse large B-cell lymphoma. Signs that this may be happening include a lymph node that suddenly grows quickly, new B symptoms (fever, night sweats, weight loss), or a rapid rise in the blood marker LDH. Transformation is confirmed with a fresh biopsy of the changing site. It changes the treatment plan from an indolent-disease approach to prompt, aggressive-lymphoma treatment. This is exactly why ongoing monitoring matters even during watch-and-wait. We cover this in depth on the follicular lymphoma transformation page; you can also review our relapsed or refractory DLBCL guidance.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.